Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Rating of “Buy” from Brokerages

Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX) have been assigned an average recommendation of “Buy” from the seven brokerages that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.30.

Several research analysts recently commented on CGTX shares. HC Wainwright lifted their target price on shares of Cognition Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, December 19th. B. Riley raised shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $1.00 to $1.50 in a research note on Thursday, December 19th. Brookline Capital Management raised shares of Cognition Therapeutics to a “strong-buy” rating in a research report on Monday, January 27th. Finally, Chardan Capital reissued a “buy” rating and set a $11.00 price objective on shares of Cognition Therapeutics in a research report on Wednesday, February 26th.

Institutional Trading of Cognition Therapeutics

A number of hedge funds have recently modified their holdings of CGTX. BIOS Capital Management LP bought a new stake in shares of Cognition Therapeutics during the 4th quarter valued at $4,208,000. Voss Capital LP bought a new stake in shares of Cognition Therapeutics during the 4th quarter valued at $351,000. Sigma Planning Corp boosted its holdings in shares of Cognition Therapeutics by 211.6% during the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock valued at $431,000 after buying an additional 417,300 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Cognition Therapeutics during the 3rd quarter valued at $27,000. Finally, Two Sigma Investments LP boosted its holdings in shares of Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after buying an additional 42,321 shares in the last quarter. Institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Stock Down 0.6 %

Shares of NASDAQ CGTX opened at $0.43 on Friday. Cognition Therapeutics has a 52 week low of $0.34 and a 52 week high of $2.95. The firm’s fifty day moving average is $0.65 and its 200 day moving average is $0.57. The company has a market cap of $17.81 million, a price-to-earnings ratio of -0.44 and a beta of 1.03.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.